Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C)

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

To understand if Mexiletine will restores normal colonic motility in a patient with irritable bowel syndrome - constipation (IBS-C) and a genetic mutation in SCN5A.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Mexiletine

Criteria

Inclusion Criteria:

• Established IBS diagnosis with a known A997T mutation in NaV1.5T

Exclusion Criteria:

• Normal 48-hour baseline transit study

• Current use of mexiletine

• Inability to stay in Rochester for 9 days for testing

• Known allergy to mexiletine

• Inability to complete daily diary

• Taking a medication known to affect myotonia, had a coexisting neuromuscular disease, or had another serious medical illness including second- or third-degree heart block, atrial flutter, atrial fibrillation, ventricular arrhythmia, history of cardiac arrhythmia requiring medication, congestive heart failure, symptomatic cardiomyopathy, or symptomatic coronary artery disease

• Inability to withdraw medications known to interact with mexiletine. Patient is currently not on any of these medications